newsfilter
← Interviews
Goldman Sachs30 min

Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech

Yvonne Greenstreet, Jerry Lee

Conference Presentation, Fireside Chat, Interview

Alnylam Pharmaceuticals leverages a decade of RNA interference research to achieve a 55% clinical success rate and recently secured approval for Amvutra to treat hereditary transthyretin-mediated amyloidosis. Under CEO Yvonne Greenstreet, the company aims to become a top-five biotech leader by 2026 through a five-year strategy to deliver 25 clinical programs and expand into common diseases like hypertension. To reach this goal, Alnylam integrates AI-driven drug design with a culture of diversity and patient advocacy to de-risk development and target tissues beyond the liver, including the central nervous system.